3 assets in Systemic Mastocytosis

Therapeutic assets addressing Systemic Mastocytosis, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Bezuclastinib Systemic Mastocytosis	Cogent Biosciences, Inc.	P2	CCC (53)
Azacitidine Systemic Mastocytosis	Blueprint Medicines Corporation	P1	CC (43)
Elenestinib Systemic Mastocytosis	Blueprint Medicines Corporation	P1	CC (43)